With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.17 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.715 whereas the lowest price it dropped to was $8.04. The 52-week range on DAWN shows that it touched its highest point at $18.07 and its lowest point at $7.88 during that stretch. It currently has a 1-year price target of $33.44. Beta for the stock currently stands at -1.27.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DAWN was up-trending over the past week, with a rise of 7.43%, but this was down by -28.99% over a month. Three-month performance dropped to -34.12% while six-month performance fell -36.58%. The stock lost -41.77% in the past year, while it has lost -31.57% so far this year. A look at the trailing 12-month EPS for DAWN yields -1.04 with Next year EPS estimates of -0.53. For the next quarter, that number is -0.41. This implies an EPS growth rate of -34.65% for this year and 61.73% for next year.
Float and Shares Shorts:
At present, 101.12 million DAWN shares are outstanding with a float of 74.28 million shares on hand for trading. On 2025-02-28, short shares totaled 18.18 million, which was 1793.0001 higher than short shares on 1738281600. In addition to Dr. Jeremy Bender M.B.A., Ph.D. as the firm’s CEO, President & Director, Mr. Charles N. York II, M.B.A. serves as its COO, CFO & Secretary.
Institutional Ownership:
Through their ownership of 0.94595003 of DAWN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, DAWN reported revenue of $29208000.0 and operating income of -$65332000.0. The EBITDA in the recently reported quarter was -$70625000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DAWN since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DAWN analysts setting a high price target of 40.0 and a low target of 24.0, the average target price over the next 12 months is 33.44444. Based on these targets, DAWN could surge 361.36% to reach the target high and rise by 176.82% to reach the target low. Reaching the average price target will result in a growth of 285.75% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.69778 being high and -$0.8473 being low. For DAWN, this leads to a yearly average estimate of -$0.72768. Based on analyst estimates, the high estimate for the next quarter is -$0.26 and the low estimate is -$0.71. The average estimate for the next quarter is thus -$0.39.
